Mgc Pharmaceuticals Stock Beta
| MGCLFDelisted Stock | USD 0.21 0.00 0.00% |
MGC Pharmaceuticals fundamentals help investors to digest information that contributes to MGC Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of MGC OTC Stock. The fundamental analysis module provides a way to measure MGC Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MGC Pharmaceuticals otc stock.
MGC |
MGC Pharmaceuticals OTC Stock Beta Analysis
MGC Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current MGC Pharmaceuticals Beta | 1.23 |
Most of MGC Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MGC Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, MGC Pharmaceuticals has a Beta of 1.2275. This is 42.73% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The beta for all United States stocks is notably lower than that of the firm.
MGC Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MGC Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of MGC Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MGC Pharmaceuticals by comparing valuation metrics of similar companies.MGC Pharmaceuticals is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MGC Pharmaceuticals will likely underperform.
MGC Fundamentals
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 24.97 M | |||
| Shares Outstanding | 2.87 B | |||
| Shares Owned By Insiders | 9.10 % | |||
| Shares Owned By Institutions | 6.12 % | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.81 X | |||
| Revenue | 4.65 M | |||
| Gross Profit | 562.87 K | |||
| EBITDA | (16.44 M) | |||
| Net Income | (20.35 M) | |||
| Cash And Equivalents | 1.89 M | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.84 % | |||
| Current Ratio | 0.84 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (12.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.23 | |||
| Market Capitalization | 17.2 M | |||
| Total Asset | 22.6 M | |||
| Z Score | 1.8 | |||
| Net Asset | 22.6 M |
About MGC Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MGC Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MGC Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MGC Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |